Abstract:Lung cancer is the leading cause of cancer-related mortality worldwide. Despite progress in the treatment of non-small-cell lung cancer, there are limited treatment options for lung squamous cell carcinoma (LUSC), compared with lung adenocarcinoma. The present study investigated the disease mechanism of LUSC in order to identify key candidate genes for diagnosis and therapy. A total of three gene expression profiles (GSE19188, GSE21933 and GSE74706) were analyzed using GEO2R to identify common differentially expressed genes (DEGs). The DEGs were then investigated using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. A protein-protein interaction (PPI) network was constructed via the Search Tool for the Retrieval of Interacting Genes/Proteins, and visualized using Cytoscape software. The expression levels of the hub genes identified using CytoHubba were validated using the University of California, Santa Cruz (UCSC) database and the Human Protein Atlas. A Kaplan-Meier curve and Gene Expression Profiling Interactive Analysis were then employed to evaluate the associated prognosis and clinical pathological stage of the hub genes. Furthermore, non-coding RNA regulatory networks were constructed using the Gene-Cloud Biotechnology information website. A total of 359 common DEGs (155 upregulated and 204 downregulated) were identified, which were predominantly enriched in ‘mitotic nuclear division’, ‘cell division’, ‘cell cycle’ and ‘p53 signaling pathway’. The PPI network consisted of 257 nodes and 2,772 edges, and the most significant module consisted of 66 upregulated genes. A total of 19 hub genes exhibited elevated RNA levels, and 10 hub genes had elevated protein levels compared with normal lung tissues. The upregulation of five hub genes (CCNB1, CEP55, FOXM1, MKI67 and TYMS; defined in Table I) were significantly associated with poor overall survival and unfavorable clinical pathological stages. Various ncRNAs, such as C1orf220, LINC01561 and MGC39584, may also play important roles in hub-gene regulation. In conclusion, the present study provides further understanding of the pathogenesis of LUSC, and reveals CCNB1, CEP55, FOXM1, MKI67 and TYMS as potential biomarkers or therapeutic targets.

Supplementary Methods, Tables 1-4, Figures 1-9 from Identification of <i>Las2</i>, a Major Modifier Gene Affecting the Pas1 Mouse Lung Tumor Susceptibility Locus

Identification of Las2, a Major Modifier Gene Affecting the Pas1 Mouse Lung Tumor Susceptibility Locus.

Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice.

Supplementary Tables 1-7 from Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Supplementary Methods, Figures S1 - S14, Tables S1, S3 - S10 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling

Supplementary Table S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Tables 1-4 from Consistent Deregulation of Gene Expression between Human and Murine <i>MLL</i> Rearrangement Leukemias

Supplementary Tables 5-8 from Consistent Deregulation of Gene Expression between Human and Murine <i>MLL</i> Rearrangement Leukemias

Functional Evaluation of Missense Variations in the Human MAD1L1 and MAD2L1 Genes and Their Impact on Susceptibility to Lung Cancer

Supplementary Tables from A Novel Micropeptide Encoded by Y-Linked LINC00278 Links Cigarette Smoking and AR Signaling in Male Esophageal Squamous Cell Carcinoma

Supplementary Tables 1-2, Figures 1-3 from Variations in <i>HSPA1B</i> at 6p21.3 Are Associated with Lung Cancer Risk and Prognosis in Chinese Populations

Supplemental Table 1 from Genetic Variation in an Mirna-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer

A Subset of Skin Tumor Modifier Loci Determines Survival Time of Tumor-Bearing Mice.

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Supplementary Figure 1, Tables 1-4 from A Second Genetic Variant on Chromosome 15Q24-25.1 Associates with Lung Cancer

Supplementary Tables 1-8 from Β-Catenin/pou5f1/sox2 Transcription Factor Complex Mediates IGF-I Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 1 from Fine-mapping of the 5p15.33, 6P22.1-P21.31, and 15q25.1 Regions Identifies Functional and Histology-Specific Lung Cancer Susceptibility Loci in African-Americans

Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Methods, Tables 1-4, Figures 1-9 from Identification of &lt;i&gt;Las2&lt;/i&gt;, a Major Modifier Gene Affecting the Pas1 Mouse Lung Tumor Susceptibility Locus